DaVita Inc. (NYSE:DVA) Shares Sold by First Trust Direct Indexing L.P.

First Trust Direct Indexing L.P. decreased its stake in DaVita Inc. (NYSE:DVA) by 8.2% in the 4th quarter, Holdings Channel reports. The firm owned 2,492 shares of the company’s stock after selling 224 shares during the quarter. First Trust Direct Indexing L.P.’s holdings in DaVita were worth $261,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hanseatic Management Services Inc. acquired a new position in shares of DaVita during the 3rd quarter worth $36,000. GAMMA Investing LLC acquired a new stake in shares of DaVita in the fourth quarter valued at approximately $60,000. Federated Hermes Inc. lifted its stake in DaVita by 1,284.4% in the 3rd quarter. Federated Hermes Inc. now owns 1,246 shares of the company’s stock valued at $118,000 after buying an additional 1,156 shares in the last quarter. Tacita Capital Inc acquired a new stake in DaVita during the 3rd quarter valued at $118,000. Finally, CENTRAL TRUST Co grew its holdings in DaVita by 93.3% during the 3rd quarter. CENTRAL TRUST Co now owns 1,448 shares of the company’s stock valued at $137,000 after buying an additional 699 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the transaction, the chief executive officer now directly owns 488,697 shares in the company, valued at $61,629,578.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the transaction, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kathleen Alyce Waters sold 11,285 shares of the stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $120.73, for a total value of $1,362,438.05. Following the completion of the sale, the insider now directly owns 81,297 shares in the company, valued at $9,814,986.81. The disclosure for this sale can be found here. Over the last three months, insiders sold 134,540 shares of company stock worth $16,551,071. Corporate insiders own 1.40% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. StockNews.com downgraded shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Monday. TheStreet raised shares of DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Truist Financial boosted their price target on DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a report on Tuesday, February 20th. Barclays lifted their price objective on DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a research report on Monday. Finally, UBS Group increased their target price on DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $121.33.

DaVita Trading Up 0.7 %

NYSE DVA opened at $137.79 on Wednesday. The company’s 50 day moving average price is $134.15 and its 200 day moving average price is $113.89. DaVita Inc. has a one year low of $71.51 and a one year high of $145.04. The company has a debt-to-equity ratio of 7.95, a quick ratio of 1.37 and a current ratio of 1.43. The firm has a market capitalization of $12.08 billion, a price-to-earnings ratio of 15.66, a PEG ratio of 1.17 and a beta of 1.04.

DaVita (NYSE:DVA) last announced its earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, beating the consensus estimate of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The company had revenue of $3.07 billion during the quarter, compared to the consensus estimate of $3.03 billion. During the same period last year, the firm earned $1.58 earnings per share. The company’s revenue was up 6.9% on a year-over-year basis. On average, sell-side analysts predict that DaVita Inc. will post 9.49 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.